David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

and Zepbound (for weight loss). Together, those two products generated $5.4 billion in sales for Eli Lilly last quarter, or 40% of the top line. Demand has been so strong that shortages of Lilly's ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...